Literature DB >> 24958966

Aspirin for primary cardiovascular prevention: when is it worth the risks?

Patricia A Howard1.   

Abstract

Low-dose aspirin is widely used by individuals to prevent first myocardial infarction and stroke. Although many health care professionals and patients believe that aspirin is safe and effective, the evidence is far from conclusive. As a result, current practice guidelines are inconsistent and leave practitioners with many unanswered questions. Because aspirin is available without prescription, pharmacists may often be the only health care professional positioned to advise and educate the patient.

Entities:  

Year:  2014        PMID： 24958966      PMCID： PMC4062728          DOI： 10.1310/hpj4906-502

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  25 in total

1.  Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD.

Authors:  Thomas Fleming; Steven E Nissen; Jeffrey S Borer; Paul W Armstrong
Journal:  Circulation       Date:  2004-01-20       Impact factor: 29.690

Review 2.  Pharmacogenetics of the antiplatelet effect of aspirin.

Authors:  Morten Würtz; Steen Dalby Kristensen; Anne-Mette Hvas; Erik Lerkevang Grove
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Per Olav Vandvik; A Michael Lincoff; Joel M Gore; David D Gutterman; Frank A Sonnenberg; Pablo Alonso-Coello; Elie A Akl; Maarten G Lansberg; Gordon H Guyatt; Frederick A Spencer
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Toward a genomic definition of aspirin resistance.

Authors:  Nanette H Bishopric
Journal:  J Am Coll Cardiol       Date:  2013-07-10       Impact factor: 24.094

5.  The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines.

Authors:  Alan D Bell; André Roussin; Raymond Cartier; Wee Shian Chan; James D Douketis; Anil Gupta; Maria E Kraw; Thomas F Lindsay; Michael P Love; Neesh Pannu; Rémi Rabasa-Lhoret; Ashfaq Shuaib; Philip Teal; Pierre Théroux; Alexander G G Turpie; Robert C Welsh; Jean-François Tanguay
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

6.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

7.  Aspirin use among adults aged 40 and older in the United States: results of a national survey.

Authors:  Michael Pignone; George K Anderson; Katherine Binns; Hugh H Tilson; Steven M Weisman
Journal:  Am J Prev Med       Date:  2007-05       Impact factor: 5.043

Review 8.  Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.

Authors:  Tracy Wolff; Therese Miller; Stephen Ko
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

9.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

10.  Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin.

Authors:  J Jaspers Focks; M M Tielemans; L G M van Rossum; T Eikendal; M A Brouwer; J B M J Jansen; R J F Laheij; F W A Verheugt; M G H van Oijen
Journal:  Neth Heart J       Date:  2014-03       Impact factor: 2.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.